Exosome Diagnostics and Therapeutics Market Size to be USD 217.6 Million till 2034; Rising Prevalence of Genetic Disorders to Boost Market Growth

Download Sample

Published Date: March 2025

Exosome diagnostics and therapeutics market is the growing industry that focuses on the use of exome sequencing for diagnosis and treatment of diseases, particularly for genetic disorders, cancer and other conditions. Exome therapeutics is the use of genetic therapies to target exome for treatment. The rising genetic disorders and rare diseases, increases the demand for exome diagnostics techniques, resulting to drive target market growth.

Exosome Diagnostics And Therapeutics Market Segmentation Analysis:

By Product Type	Reagents & Kits, Instruments, and Software
By Source	Blood & Blood Plasma, Stem Cells, and Urine
By Application	Diagnostics and Therapeutics
By End-User	Hospitals & Clinics, Research Institutions, and Pharmaceutical companies

Exosome Diagnostics And Therapeutics Market??????? Report Highlights:

Exosome diagnostics and therapeutics market size was valued at USD 89.2 Million in 2024.
The market is projected to be Worth USD 217.6 Million and is growing at a CAGR of 10.3%.
Based on product type, reagents and kits segment is expected to dominate in market.
On the basis of source, the blood and blood plasma segment hold the largest share in market.
Diagnostics segment dominates in the market, under application segmentation.
Based on end-user, the hospitals & clinics segment is leading the market growth.
North America holds the major share in focused market.

Exosome Diagnostics And Therapeutics Market Dynamics:

Growing Factor	Challenge Factor	Market Trend
Advances in Next-Generation Sequencing (NGS) Technologies	Complexity of Data Interpretation	Integration of Artificial Intelligence and Machine Learning

Exosome Diagnostics And Therapeutics Market Key Highlights

In March 2024, UNIVERCELLS TECHNOLOGIES (Belgium) and BIONET (China), two leading participants in Taiwan's regenerative medicine sector, collaborated to integrate the latter's scale-X fixed-bed bioreactor. By employing the scale-X hydro system, BIONET aims to optimize the production of extracellular vesicles (including exosomes) generated by MSCs for therapeutic applications. This suggests a potential advancement in the large-scale manufacturing of standardized exosome-based pharmaceuticals.

Exosome Diagnostics And Therapeutics Market Report Analysis:

Market Expansion Strategies-

·For instance, in December 2024, GeneDx collaborated with Biogen and Stoke Therapeutics for the funding of USD 90 Million, to develop Patient Access Program for pediatric epilepsy, which provides access to whole exome sequencing. The Patient Access Program aimed to address overcome lack of access to obtain genetic diagnosis for rare disorders challenges by increasing access to whole exome sequencing for pediatric epilepsy patients.

·For instance, in August 2024, Ambry Genetics launched new Multiomic ExomeReveal test. Whole Exome Sequencing and targeted gene panel sequencing helps to detect small germline variants, such as Single Nucleotide Variants and insertions/deletions. A new multiomic exome sequencing test for rare disease is aimed to detect genetic disorder and expand the number of diagnoses process.

Browse ∼50 market data tables and ∼35 figures through ∼180 slides and in-depth TOC on “Exosome diagnostics and therapeutics Market, By Product Type (Reagents & Kits, Instruments, and Software), Source (Blood & Blood Plasma, Stem Cells, and Urine), Application (Diagnostics and Therapeutics), End-User (Hospitals & Clinics, Research Institutions, and Pharmaceutical companies), and Region - Trends, Analysis, and Forecast till 2034”

For more insights into the Exosome diagnostics and therapeutics Market and its future trends, visit the link: https://www.prophecymarketinsights.com/market_insight/exosome-diagnostics-and-therapeutics-market-5330

Competitive Landscape of Exosome diagnostics and therapeutics Market:

The key players operating in the exome diagnostics and therapeutics market Thermo Fisher Scientific Malvern Instruments, Aethlon Medical, Inc., Lonza Group (HansaBioMed Life Sciences Ltd., Exiqon A/S, NanoSomix, AMS Biotechnology, Miltenyi Biotec, NX Pharmagen, Codiak BioSciences Inc., Aegle Therapeutic, AcouSort AB, Exosome Diagnostics, System Biosciences, Exosome Sciences, and Capricor Therapeutic.